Core Insights - Nurix Therapeutics (NRIX) is positioned to make significant advancements in the treatment of Chronic Lymphocytic Leukemia (CLL) and immune diseases, indicating a potential shift in therapeutic approaches within this market [1] Industry Overview - The CLL treatment market has been predominantly controlled by BTK inhibitors, specifically Ibrutinib and Pirtobrutinib, highlighting the competitive landscape and the challenges faced by new entrants [1]